AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IRWD · NASDAQ · Drug Manufacturers - Specialty & Generic

Ironwood Pharmaceuticals

Develops gastrointestinal therapies around LINZESS and apraglutide.

$4.12

After-hours close−0.00 (−0.06%)

At close$4.12(−2.83%)

Something off on this page? Send us feedback.

Profile

Ironwood Pharmaceuticals, Inc.IRWDHealth Care

Builds its business around LINZESS, a prescription treatment for IBS-C and CIC, and a partner-led commercialization model. Develops apraglutide for adults with short bowel syndrome and intestinal failure.

Commercializes LINZESS, its in-house-discovered linaclotide product for adults with IBS-C and CIC. AbbVie leads commercialization in the United States, while AstraZeneca covers China and Astellas covers Japan.

Develops apraglutide, a long-acting synthetic GLP-2 analogue, for adults with short bowel syndrome and intestinal failure. Access to the program is limited to clinical trials as the STARS program continues.

Operates as a single human-therapeutics segment with one mature commercial franchise and a rare-disease pipeline expansion. The model depends on the LINZESS collaboration's shared sales and cost structure and on confirmatory clinical and regulatory progress for apraglutide.

Company facts

CEOThomas McCourt

ListedFeb 3, 2010

ExchangeNASDAQ

HeadquartersBoston, MA

CountryUnited States

Employees100

CIK0001446847

ISINUS46333X1081

Key statistics

Market cap$679.9M

EPS (ttm)$0.7672

P/E (ttm)5.38

ROE-57.4%

P/B−4.22

P/S1.75

Dividend yield—

Beta1.93vs XLV 0.69

Year to date −3.5% · Average volume (30d) 2.0M

Analysts

Price target, next 12 months$5.00+21.1%Median of 30 analysts · vs the Aug 28 close

ConsensusHold11 of 30 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $4.13

High$18.00+335.8%

Median$5.00+21.1%

Low$1.00−75.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Feb 26, 2026	Jefferies	Target				$3.70
Jan 5, 2026	Craig-Hallum	Target			$3.80	$5.70
Jan 5, 2026	Citizens	Upgrade	Market Perform	Market Outperform
Jan 4, 2026	Wells Fargo	Target			$7	$5
Nov 26, 2025	Craig-Hallum	Target				$3.80

Earnings

EPS

Estimate$0.30

ReportedDue Nov 9, 2026

Revenue

Estimate$120.0M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.32	$0.31	−3.1%	$114.8M	$113.0M	−1.6%	+2.65%
May 7, 2026Q1 FY26	$0.07	$0.24	+242.9%	$92.1M	$106.5M	+15.6%	+1.20%
Feb 25, 2026Q4 FY25	$0.02	−$0.01	−150.0%	$50.9M	$47.7M	−6.3%	+8.93%
Nov 10, 2025Q3 FY25	$0.09	$0.24	+166.7%	$50.9M	$122.1M	+139.6%	+14.23%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$41.1M	$85.2M	$122.1M	$47.7M	$106.5M	$113.0M
Gross profit	$13.7M	$84.8M	$121.6M	$47.7M	$106.1M	$113.0M
Operating income	−$29.1M	$45.1M	$77.7M	$6.6M	$72.5M	$79.3M
Net income	−$37.4M	$23.6M	$40.1M	−$2.3M	$40.8M	$51.3M
Diluted EPS	−$0.23	$0.14	$0.23	−$0.01	$0.24	$0.31
Gross margin	33.3%	99.5%	99.6%	100.0%	99.6%	100.0%
Operating margin	-70.7%	52.9%	63.6%	13.7%	68.1%	70.2%

Fiscal years (4-quarter sums)FY21 $413.8M · FY22 $410.6M · FY23 $442.7M · FY24 $351.4M · FY25 $296.2M

Revenue by product · Q2 FY26

Royalty$1.1M · 73%

Collaborative Arrangement, Collaboration And License Agreements$397.0K · 27%

Revenue by geography · Q2 FY26

North America$110.9M · 99%

Europe And Other$1.1M · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $79.1M · Total debt $396.9M · Total assets $285.1M · Shareholders' equity −$161.8M

Dividends

No dividends on record.

Ownership

Institutions 99.55%Insiders 10.10%

Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.

Shares outstanding 164.61M · Float —

Float — provider float is below the insider stake.

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	17.79M	10.81%	13F	Aug 7, 2026
Armistice Capital, LLC	13.93M	8.46%	13F	Aug 14, 2026
Pacer US Small Cap Cash Cows ETF	11.71M	7.31%	13G	May 2, 2025
Alexander J. Denner · director	9.44M	5.74%	Form 4	Jun 17, 2026
Sarissa Capital Management LP	9.19M	5.58%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jul 7, 2026	Ronald Silver	officer: PFO & PAO	−127,890	$4.52
Jun 16, 2026	Julie McHugh	director	−21,571	$3.73
Mar 17, 2026	Alexander J. Denner	director	−6,730,800	$3.05
Feb 24, 2026	Ronald Silver	officer: Principal Accounting Officer	−12,621	$3.66
Feb 23, 2026	Ronald Silver	officer: Principal Accounting Officer	−11,552	$3.81